(Reuters) - Private equity firm Pamplona Capital Management is nearing a deal to buy contract drug research firm Parexel International Corp for $4.6 billion, the Wall Street Journal reported on Tuesday.
Pamplona is set to pay $88.10 a share in cash as part of the deal, the newspaper said citing people familiar with the matter. (http://on.wsj.com/2slumT7)
Activist investor Starboard Value LP reported a 5.7 percent stake in Parexel in May, saying the company's shares were "undervalued" and represented an attractive investment opportunity.
Corvex Management LP, another prominent activist investor, owns a significant stake in Parexel as well, sources told Reuters in May, and also believes the company should sell itself.
Up to Monday's close, shares of Parexel had risen nearly 22 percent since reports in early May that the company was exploring a sale.
Pamplona and Parexel were not immediately available to comment outside regular U.S. business hours.
(Reporting by Subrat Patnaik in Bengaluru; Editing by Amrutha Gayathri)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
